Cyclerion Shares to Watch With Deal in Focus as Markets Reopen
Cyclerion closed Friday at $3.18, up 0.6%, ahead of a planned all-stock merger with Korsana Biosciences expected to close in the third quarter. Cyclerion shareholders are set to receive about 1.5% of the combined company, with the rest going to Korsana holders and new investors. Korsana has secured $380 million in financing to fund Alzheimer’s drug development through 2027. No new announcements were made Friday.